Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.36 |
| ▸ | AURKA | O14965 | 5/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520021 | 1.00 | KDR (0.40) | KDRCHEK1AURKABCHEMAOA | |
| SCHEMBL15520212 | 0.89 | KDR (0.43) | KDRCHEK1AURKA | |
| SCHEMBL15520143 | 0.88 | KDR (0.45) | KDRCHEK1AURKA | |
| SCHEMBL15520382 | 0.87 | KDR (0.41) | KDRCHEK1AURKA | |
| SCHEMBL15520654 | 0.86 | KDR (0.37) | KDRCHEK1AURKA | |
| SCHEMBL15520718 | 0.84 | KDR (0.43) | KDRCHEK1AURKABCHEMAOA | |
| SCHEMBL15520020 | 0.84 | KDR (0.43) | KDRCHEK1AURKABCHEMAOA | |
| SCHEMBL15520611 | 0.83 | KDR (0.49) | KDRCHEK1AURKA | |
| SCHEMBL4020827 | 0.82 | KDR (0.38) | KDRCHEK1AURKA | |
| SCHEMBL15520682 | 0.81 | CHEK1 (0.50) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | KDR 1088/4885CHEK1 1/4885AURKA 7/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885CHEK1 2/4885AURKA 11/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | KDR 1088/4885CHEK1 1/4885AURKA 7/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885CHEK1 2/4885AURKA 11/4885 |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | KDR 1159/4885CHEK1 2037/4885AURKA 1818/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | KDR 1813/4885CHEK1 2/4885AURKA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.